PDS BIOTECHNOLOGY ($PDSB) posted quarterly earnings results on Thursday, March 27th. The company reported earnings of -$0.21 per share, beating estimates of -$0.28 by ...
(1) To reflect a non-cash charge to operating expense for selling, general, and administrative stock-based compensation. (2) To reflect a non-cash charge to operating expense for research and ...
- Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME ...
Nautilus Biotechnology, Inc. has announced that it will release its financial results for the second quarter of 2025 on July 31, 2025, before the market opens. Following the announcement, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback